

bluebird bio, Inc.
Form 4
June 26, 2013

FORM 4

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287
Expires: January 31, 2015
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *
Polack Axel

(Last) (First) (Middle)

TVM V LIFE SCIENCE
VENTURES GMBH &
CO., MAXIMILIANSTRASSE 35,
ENTRANCE C

(Street)

MUNICH, 2M 80539

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
bluebird bio, Inc. [BLUE]

3. Date of Earliest Transaction
(Month/Day/Year)
06/24/2013

4. If Amendment, Date Original Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

Director 10% Owner
 Officer (give title below) Other (specify below)

6. Individual or Joint/Group Filing(Check Applicable Line)
 Form filed by One Reporting Person
 Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Ownership (Instr. 4)
Common Stock	06/24/2013		C	(A) Amount \$ 0	(D) Price 2,254,357	I	See footnote (2)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474 (9-02)

Edgar Filing: bluebird bio, Inc. - Form 4

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Underlying (Instr. 3 and 4)
					(A)	(D)	Date Exercisable	Expiration Date	
Series A-1 Convertible Preferred Stock	(3)	06/24/2013		C		6,169,117	(3)	(3)	Common Stock
Series A-2 Convertible Preferred Stock	(3)	06/24/2013		C		11,835,834	(3)	(3)	Common Stock
Series B Convertible Preferred Stock	(3)	06/24/2013		C		17,749,014	(3)	(3)	Common Stock
Series C Convertible Preferred Stock	(3)	06/24/2013		C		3,994,248	(3)	(3)	Common Stock
Series D Convertible Preferred Stock	(3)	06/24/2013		C		3,010,234	(3)	(3)	Common Stock
Warrant to Purchase Series A-1 Stock (right to buy)	\$ 0.6619	06/24/2013		J ⁽⁴⁾		660,982	(5)	11/16/2015	Series A Convertible Preferred Stock
Warrant to Purchase Common Stock (right to buy)	\$ 12.55	06/24/2013		J ⁽⁴⁾	34,849		(5)	11/16/2015	Common Stock
Warrant to Purchase Series A-1 Stock (right to buy)	\$ 0.6619	06/24/2013		J ⁽⁴⁾		440,650	(5)	10/26/2016	Series A Convertible Preferred Stock
	\$ 12.55	06/24/2013		J ⁽⁴⁾	23,232		(5)	10/26/2016	

Edgar Filing: bluebird bio, Inc. - Form 4

Warrant to Purchase Common Stock (right to buy)									Common Stock
Warrant to Purchase Series A-1 Stock (right to buy)	\$ 0.6619	06/24/2013	J ⁽⁴⁾	1,038,674	<u>(5)</u>	05/03/2017			Series A Convertible Preferred Stock
Warrant to Purchase Common Stock (right to buy)	\$ 12.55	06/24/2013	J ⁽⁴⁾	54,760	<u>(5)</u>	05/03/2017			Common Stock
Warrant to Purchase Series A-1 Stock (right to buy)	\$ 0.6619	06/24/2013	J ⁽⁴⁾	236,062	<u>(5)</u>	08/28/2018			Series A Convertible Preferred Stock
Warrant to Purchase Common Stock (right to buy)	\$ 12.55	06/24/2013	J ⁽⁴⁾	12,445	<u>(5)</u>	08/28/2018			Common Stock
Warrant to Purchase Series A-1 Stock (right to buy)	\$ 0.6619	06/24/2013	J ⁽⁴⁾	236,062	<u>(5)</u>	12/18/2018			Series A Convertible Preferred Stock
Warrant to Purchase Common Stock (right to buy)	\$ 12.55	06/24/2013	J ⁽⁴⁾	12,445	<u>(5)</u>	12/18/2018			Common Stock
Warrant to Purchase Series A-1 Stock (right to buy)	\$ 0.6619	06/24/2013	J ⁽⁴⁾	462,681	<u>(5)</u>	04/15/2019			Series A Convertible Preferred Stock
Warrant to Purchase Common Stock (right to buy)	\$ 12.55	06/24/2013	J ⁽⁴⁾	24,393	<u>(5)</u>	04/15/2019			Common Stock
	\$ 0.3262	06/24/2013	J ⁽⁶⁾	287,400	<u>(5)</u>	04/15/2019			

Warrant to
Purchase
Series B
Stock (right
to buy)

Series I
Convertible
Preferred
Stock

Warrant to
Purchase
Common
Stock (right
to buy)

\$ 6.19 06/24/2013 J⁽⁶⁾ 15,152 ⁽⁵⁾ 04/15/2019

Common
Stock

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Polack Axel TVM V LIFE SCIENCE VENTURES GMBH & CO. MAXIMILIANSTRASSE 35, ENTRANCE C MUNICH, 2M 80539	X			

Signatures

/s/ Linda C. Bain,
Attorney-in-Fact 06/26/2013

 **Signature of Reporting Person

 Date

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) Represents the total number of shares received upon conversion of shares of the Issuer's Series A-1 Convertible Preferred Stock (the "Series A-1 Shares"), Series A-2 Convertible Preferred Stock (the "Series A-2 Shares"), Series B Convertible Preferred Stock (the "Series B Shares"), Series C Convertible Preferred Stock (the "Series C Shares") and Series D Convertible Preferred Stock (the "Series D Shares") and together with the Series A-1 Shares, the Series A-2 Shares, the Series B Shares and the Series C Shares, collectively, the "Preferred Shares").

(2) The securities are held directly by TVM V Life Science Ventures GmbH & Co. KG. ("TVM V"). The Reporting Person is an authorized officer of TVM V's general partner, TVM Capital GmbH, and disclaims beneficial ownership of all shares held by the foregoing entities except to the extent of his pecuniary interest therein.

(3) Effective upon the closing of the Issuer's initial public offering of its Common Stock, each Preferred Share automatically converted at a ratio of 18.967-to-one into the number of shares of Common Stock shown in column 7. The Preferred Shares had no expiration date.

(4) Upon completion of the Issuer's initial public offering, the warrant to purchase shares of Series A-1 Preferred Stock automatically converted on an 18.967-for-one basis into a warrant to purchase shares of Common Stock. Disposition of the Warrant to Purchase Series A-1 Preferred Stock and acquisition of the Warrant to Purchase Common Stock is listed solely for the purpose of reporting such conversion of the shares underlying the security.

(5) This warrant is immediately exercisable.

(6) Upon completion of the Issuer's initial public offering, the warrant to purchase shares of Series B Preferred Stock automatically converted on an 18.967-for-one basis into a warrant to purchase shares of Common Stock. Disposition of the Warrant to Purchase Series B Preferred Stock and acquisition of the Warrant to Purchase Common Stock is listed solely for the purpose of reporting such conversion of the shares underlying the security.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Edgar Filing: bluebird bio, Inc. - Form 4

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.